Company intelligence / Profile preview
Oblato, Inc.
New Jersey, United Statesoblatoinc.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Oblato’s lead program, OKN-007, is in ongoing clinical development for brain cancers. The injectable formulation has completed patient enrollment in a Phase 2 trial for recurrent GBM in combination with temozolomide. An oral formulation entered Phase 1 trials for recurrent high-grade glioma patients as of April 2023. The company has received rare pediatric disease and fast track designations from the FDA for DIPG. Some patients are still under treatment or follow-up from previous studies.
- Therapeutic areas
- Oncology
- Modalities
- Small molecules
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Academic/clinical partnerships include multiple U.S. institutions such as Henry Ford Health System participating in clinical trials; original licensing agreement with Oklahoma Medical Research Foundation (OMRF) for rights to OKN‑007. No major pharma co-development deals disclosed.
Beyond the preview
Go deeper on Oblato, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Oblato, Inc..